Envoy Medical Expands Patent Portfolio Globally

Envoy Medical® Inc., a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents. This portfolio consists of 40 U.S. and 57 foreign patents. In addition, the Company has 26 pending foreign applications and 9 pending U.S. applications. Envoy Medical® has now a total of 35 pending applications, with 26 of these being foreign applications and 9 being U.S. applications.

This patent covers technology related to characterizing electrical conductors within an implantable cochlear system and supports the Company's strategy for future developments in integrated implantable hearing technology.

This patent covers systems and methods designed to compensate for variability in a middle ear sensor, including techniques for processing and normalizing signals received from the sensor. This patent helps protect Envoy Medical's approach of using technology that works with the ear to pick up sound, rather than a microphone.

Envoy Medical's intellectual property portfolio spans technologies and ideas supporting current developments as well as future improvements of its fully implanted hearing platform or technology, including sensing, signal processing, implantation, and system integration. The portfolio now consists of 40 U.S. granted patents, 57 foreign granted patents, and 97 total granted patents globally. The foreign patent count includes, for granted European cases, the European Patent ("EP") separately from and in addition to corresponding individual country validations and unitary patents.

Envoy Medical, a hearing health company focused on providing innovative technologies across the hearing loss spectrum, has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

The investigational fully implanted Acclaim Cochlear Implant (CI) is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

The Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI) is the only FDA-approved, fully implanted hearing device for adults diagnosed with moderate to severe sensorineural hearing loss, allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.

Envoy Medical's success in retaining or recruiting key officers, key employees, or directors is not mentioned in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not addressed in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not mentioned in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not addressed in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not mentioned in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not addressed in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not mentioned in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not addressed in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not mentioned in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not addressed in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not mentioned in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not addressed in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not mentioned in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not addressed in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not mentioned in the press release. The company's success in retaining or recruiting key officers, key employees, or directors is not addressed in the press release.